» Articles » PMID: 39479007

Anatomy-guided Resections for Paralimbic Tumors in the Temporo-insular Region: Combining Tumor and Epilepsy Surgery Concepts

Overview
Journal Front Neurol
Specialty Neurology
Date 2024 Oct 31
PMID 39479007
Authors
Affiliations
Soon will be listed here.
Abstract

Object: Tumors in the temporo-mesial region often extend into the insula and vice versa. The present study investigated the results of a surgical strategy that combines principles of tumor and epilepsy surgery.

Methods: We retrospectively analyzed 157 consecutive patients with intrinsic brain tumors in the temporo-mesial region, with varying degrees of extensions into the insula (44 patients, 28.0%). The surgical strategy utilized "anatomy-guided resection," targeting specific anatomical compartments infiltrated by the tumor (e.g., temporal pole, anterior temporo-mesial region = uncus and hippocampal head, posterior temporo-mesial, insula) rather than treating the tumor as a single mass.

Results: The most frequent histologies were ganglioglioma CNS WHO grade 1 (55 patients, 35.0%) and IDH1 wildtype glioblastoma (36 patients, 22.9%). Tumor infiltration was most commonly found in the anterior temporo-mesial compartment (145 patients, 92.4%). An anterior temporal lobectomy was part of the surgical strategy in 131 cases (83.4%). Seventy-six patients (48.4%) with drug-resistant epilepsy underwent a formal presurgical epilepsy work-up, including depth electrode placement in three cases. Complete resections were achieved in 117 patients (74.5%), with supramarginal resections performed in 89 cases (56.7%). Four patients experienced non-temporary neurological complications (CTCAE grade 3-5). At 6 months, 127 of 147 assessable patients (86.4%) were free from seizures or auras (ILAE class 1), excluding early postoperative seizures (<30 days). At 24 months, 122 of 144 assessable cases (84.7%) remained seizure-free (ILAE class 1). Kaplan-Meier estimates for 5-year overall survival were 98.5% for non-recurrent glioneuronal tumors. The 2-year overall survival estimates were 96.0% for 24 primary diffuse CNS WHO grade 2 and 3 gliomas and 55.2% for 30 patients undergoing first surgeries for glioblastomas/astrocytomas CNS WHO grade 4.

Conclusion: Combining both epilepsy and tumor surgery concepts in the surgical treatment of intrinsic brain tumors involving the mesial temporal lobe, often extending into the insula, led to more extensive resections, improved seizure outcomes, and potentially even better patient survival outcomes.

Citing Articles

Spatial invasion patterns of temporal lobe glioblastoma after complete resection of contrast-enhancing tumor.

Fares J, Wan Y, Gurung B, Nazar T, Mair R, Joannides A J Neurooncol. 2025; .

PMID: 40045105 DOI: 10.1007/s11060-025-04991-5.

References
1.
Xie M, Wang X, Qiao J, Zhou J, Guan Y, Liu C . The long-term surgical outcomes of low-grade epilepsy-associated neuroepithelial tumors. Epilepsia Open. 2022; 7(4):697-709. PMC: 9712488. DOI: 10.1002/epi4.12648. View

2.
Gousias K, Schramm J, Simon M . Extent of resection and survival in supratentorial infiltrative low-grade gliomas: analysis of and adjustment for treatment bias. Acta Neurochir (Wien). 2013; 156(2):327-37. DOI: 10.1007/s00701-013-1945-0. View

3.
Solomons M, Jaunmuktane Z, Weil R, El-Hassan T, Brandner S, Rees J . Seizure outcomes and survival in adult low-grade glioma over 11 years: living longer and better. Neurooncol Pract. 2020; 7(2):196-201. PMC: 7081389. DOI: 10.1093/nop/npz056. View

4.
Lassman A, Hoang-Xuan K, Polley M, Brandes A, Cairncross J, Kros J . Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors. J Clin Oncol. 2022; 40(23):2539-2545. PMC: 9362869. DOI: 10.1200/JCO.21.02543. View

5.
Ersoy T, Ridwan S, Grote A, Coras R, Simon M . Early postoperative seizures (EPS) in patients undergoing brain tumour surgery. Sci Rep. 2020; 10(1):13674. PMC: 7426810. DOI: 10.1038/s41598-020-70754-z. View